A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

This phase I/II trial is studying the side effects and best dose of elotuzumab and to see how well it works when given with lenalidomide, bortezomib, and dexamethasone in treating patients with multiple myeloma.

Key Eligibility:

• Patients must have newly diagnosed active multiple myeloma (MM)

• Patients with non-secretory MM or known amyloidosis are not eligible

• Patients must have measurable disease within 28 days prior to registration

• Zubrod performance status less than or equal to 2
Phase I/II
Alison Conlin, M.D.
Laurie Delanty

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.